Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...

Reckitt Benckiser is continuing to assess options for its nutrition operations housing the Mead Johnson infant-formula business.

Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over allegations their premature infant formula can cause a serious gut condition.

The stable outlook reflects Moody’s base case expectations that Reckitt’s gross debt/EBITDA leverage will stay at or below 2.5x, and that the company’s competitive position will continue to support ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

In March 2024, a U.S. court in Illinois awarded $60 million in damages to a mother of a baby that died from necrotizing ...

Reckitt has shown a medium-term uptrend since April 2024, outperforming peers, but litigation risks from Mead Johnson remain substantial, making the stock a hold. Reckitt's strategic focus on high ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Missouri 22nd Judicial Circuit Court Judge Michael Noble granted the plaintiff's motion for a new trial on Thursday, citing ...